White House Denys Rumors Trump Is on Experimental Weight Loss Drug
A report about a 79-year-old man receiving early access to an unapproved weight loss drug through an FDA emergency pathway set off a wave of online speculation this week — and the White House came out swinging to shut it down.
The report from health outlet STAT revealed that a senior NIH clinician named Ranganath Muniyappa had requested access to retatrutide — Eli Lilly's experimental weight loss drug — for an unnamed 79-year-old patient back in April through the FDA's compassionate use program. The request cited a diagnosis of refractory obesity with obstructive sleep apnea and pulmonary hypertension. Sources told STAT the application drew unusual attention from top health officials, suggesting the patient was well-connected.
Trump turned 80 on June 14. The math wasn't subtle.
STAT reporter Lizzy Lawrence posted on X that she asked the White House directly whether the patient was Trump — and didn't get a direct answer. The White House rapid-response account reposted her message with: "No, it wasn't President Trump — and you people are truly sick and deranged."
White House spokesman Kush Desai was more pointed, writing that Lawrence had "proven herself to be an unserious gossip columnist" and stating plainly: "This application was not for the President."
What Retatrutide Actually Is
Most people have heard of Ozempic and Wegovy. Retatrutide is the next generation beyond those — and the early numbers on it are eye-catching.
While Ozempic and Wegovy target a single hormone receptor called GLP-1, retatrutide is a triple agonist — it hits GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 clinical trials published in the New England Journal of Medicine showed participants losing an average of 24% of their body weight over about a year — significantly more than current approved options. The drug also showed substantial improvements in type 2 diabetes markers.
It has not been approved by the FDA. Millions of Americans with obesity are currently waiting for that approval, and the compassionate use pathway — officially called Expanded Access — exists specifically for situations where a patient with a serious condition can't wait for the standard approval process and has no comparable alternatives available. It's not commonly granted and requires physician sponsorship, detailed medical justification, and FDA review.
Trump's Health and Weight — What's Actually on Record
Trump's most recent physical exam results were released May 29 by White House physician Dr. Sean Barbabella, who wrote that the president "remains in excellent health" with "strong cardiac, pulmonary, neurological, and overall physical function" and is "fully fit to carry out all duties of the Commander-in-Chief."
Trump's weight was listed at 238 lbs in May's results. His April 2025 exam had him at 224 lbs — down 20 lbs from his first term weight of 244 lbs in 2020. At 75 inches tall and 238 lbs, the CDC's BMI calculator places him in the overweight category, though BMI has significant limitations as a health metric.
The exam's preventive care section noted guidance on diet, a recommendation to take low-dose aspirin, increased physical activity, and "continued weight loss."
Trump told reporters in January that he had never taken a GLP-1 weight loss drug like Wegovy or Zepbound, but added — notably — "I probably should." He has publicly named members of his own administration who do take weight loss drugs and has been an active proponent of making them cheaper and more accessible for Americans.
The Eli Lilly Connection That Made This More Interesting
What added fuel to the speculation was a separate report in May confirming Trump had invested in Eli Lilly — the company that makes retatrutide — earlier this year. The Trump administration also announced a deal with Eli Lilly and Novo Nordisk to reduce GLP-1 drug costs for Americans through a program called TrumpRx, with prices ranging from $149 per month for oral versions to $350 per month for injections, with lower rates for Medicare and Medicaid recipients starting mid-2026.
A president who invested in Eli Lilly, struck a drug pricing deal with Eli Lilly, and is 80 years old and overweight by BMI standards — it wasn't hard to see why people connected the dots to an unapproved Eli Lilly drug being accessed through an emergency FDA pathway by an anonymous 79-year-old with obesity and sleep apnea.
The White House says those dots don't connect. The identity of the actual patient hasn't been confirmed publicly.
Curious for more stories that keep you informed and entertained? From the latest headlines to everyday insights, YourLifeBuzz has more to explore. Dive into what’s next.